Retained Earnings (Accumulated Deficit) of NeuroSense Therapeutics Ltd. from 31 Dec 2022 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
NeuroSense Therapeutics Ltd. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2022 to 30 Jun 2025.
  • NeuroSense Therapeutics Ltd. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Jun 2025 was $41,369,000, a 28% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

NeuroSense Therapeutics Ltd. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $41,369,000 -$8,987,000 -28% 30 Jun 2025 6-K 01 Aug 2025 2025 Q2
Q4 2024 $36,660,000 -$10,539,000 -40% 31 Dec 2024 6-K 01 Aug 2025 2025 Q2
Q2 2024 $32,382,000 30 Jun 2024 6-K 30 Sep 2024 2024 Q2
Q4 2023 $26,121,000 -$10,107,000 -63% 31 Dec 2023 20-F 07 Apr 2025 2024 FY
Q4 2022 $16,014,000 31 Dec 2022 6-K 17 Jun 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.